DMD+Sources

=Sources:=

Angelini, C., Tasca, E. (2015). Drugs in development and dietary approach for Duchenne muscular dystrophy. DovePress. [|Volume 2015:5] Pages 51-60.

[]

Arpan I, Willcocks RJ, Forbes SC, et al. Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology. 2014;83:974–80.

Bladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., Kosma, K., … Lochmüller, H. (2015). The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations. Human Mutation, 36(4), 395–402. http://doi.org/10.1002/humu.22758

Garralda, M. E., McConachie, H., Le Couteur, A., Sriranjan, S., Chakrabarti, I., Cirak, S., & ... Muntoni, F. (2013). Emotional impact of genetic trials in progressive paediatric disorders: a dose-ranging exon-skipping trial in Duchenne muscular dystrophy. Child: Care, Health & Development, 39(3), 449-455. doi:10.1111/j.1365-2214.2012.01387.x

Lim, K. R. Q., Maruyama, R., & Yokota, T. (2017). Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Design, Development and Therapy, 11, 533–545. [|http://][|doi.org/10.2147/DDDT.S97635]

National Center for Biotechnology Information (NCBI). Retrieved Jan.-March 2017 from: https://www.ncbi.nlm.nih.gov/gene/1756

Ruff, S. (2016). Eteplirsen NDA 206488, Peripheral and Central Nervous System Drug Advisory Committee. Retrieved from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM500822.pdf

Abstract Materials and Methods Results Discussion Broader Impact (back)